Chronic myeloid leukaemia

  title={Chronic myeloid leukaemia},
  author={Ruediger Hehlmann and A. Hochhaus and M. Baccarani and on behalf of the European LeukemiaNet},
  journal={The Lancet},
  • Ruediger Hehlmann, A. Hochhaus, +1 author on behalf of the European LeukemiaNet
  • Published 2007
  • Medicine
  • The Lancet
  • Chronic myeloid leukaemia (CML) was the first neoplastic disease for which knowledge of the genotype led to a rationally designed therapy. As a result of its well known pathophysiology, straightforward diagnosis, well established prognostic factors, and treatment for the cause of disease, CML has been studied to an extent that far exceeds that expected from its frequency, and serves as a model disease for other cancers. Imatinib, an inhibitor of BCR-ABL tyrosine kinase, has revolutionised… CONTINUE READING
    473 Citations

    Topics from this paper

    Chronic Myeloid Leukemia--Prognostic Value of Mutations.
    • 17
    • PDF
    What is the best pharmacotherapeutic strategy for treating chronic myeloid leukemia in the elderly?
    • 1
    Nilotinib for the treatment of chronic myeloid leukemia
    • 13
    Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.
    • 563
    Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™)
    • 52
    Current role of stem cell transplantation in chronic myeloid leukaemia.
    • 50
    Chronic myeloid leukemia
    • 7


    Chronic myeloid leukemia: a model for oncology
    • 57
    Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
    • 1,988
    Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia.
    • 39
    Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
    • 1,213
    • PDF
    Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
    • 3,107
    • PDF